Skip to main content
Akero Therapeutics, Inc. logo

Akero Therapeutics, Inc. — Investor Relations & Filings

Ticker · AKRO ISIN · US00973Y1082 LEI · 549300SI3KG74LBE2955 US Professional, scientific and technical activities
Open in API
Filings indexed 719 across all filing types
Latest filing 2021-06-30 Director's Dealing
Country US United States of America
Listing US AKRO

About Akero Therapeutics, Inc.

https://akerotx.com/

Akero Therapeutics, Inc. is a clinical-stage company focused on developing and commercializing transformational treatments for patients with serious metabolic diseases characterized by high unmet medical need. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21 (FGF21). EFX is being evaluated in multiple clinical trials as a potential foundational therapy for metabolic dysfunction-associated steatohepatitis (MASH), a severe form of liver disease. The program aims to provide a differentiated treatment that addresses the complex pathophysiology of MASH by restoring metabolic balance.

Recent filings

Filing Released Lang Actions
PRIMARY DOCUMENT
Director's Dealing
2021-06-30 English
SC 13D/A
Major Shareholding Notification
2021-06-29 English
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce unscheduled material events or corporate changes. The text includes references to a press release about clinical study results and presentations at a scientific conference, but it does not contain comprehensive financial statements or detailed financial analysis. It is not an Annual Report (10-K), Interim Report (IR), or Earnings Release (ER). The document primarily serves as a regulatory announcement of recent events and disclosures, consistent with the purpose of Form 8-K filings. Therefore, the appropriate classification is Regulatory Filings (RNS). The document length (8984 characters) and content confirm it is not merely a brief announcement but a full Form 8-K filing, reinforcing the RNS classification with high confidence.
2021-06-25 English
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce unscheduled material events or corporate changes. The text includes references to a press release about clinical trial results and analyses presented at a conference, but it does not contain comprehensive financial statements or detailed financial performance data typical of an Annual Report (10-K) or Interim Report (IR). It also does not fit categories like Earnings Release (ER) since it is not a quarterly financial summary, nor does it fit Management Reports (MDA) or Investor Presentation (IP) as it is a regulatory filing form. The document is primarily an announcement of a material event and includes forward-looking statements and risk factors, typical of an 8-K filing. Therefore, the best classification is Regulatory Filings (RNS), which is the fallback category for miscellaneous SEC filings like Form 8-K that do not fit other specific categories. The document length (9538 characters) and content confirm it is not a brief announcement or a report publication announcement (RPA).
2021-06-21 English
FORM 4 SUBMISSION
Director's Dealing
2021-06-04 English
OWNERSHIP DOCUMENT
Director's Dealing
2021-06-03 English

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.